- Home
- NGNE vs PDYN Comparison
NGNE vs PDYN Comparison
Compare NGNE & PDYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- PDYN
- Stock Information
- Founded
- NGNE 2003
- PDYN 1983
- Country
- NGNE United States
- PDYN United States
- Employees
- NGNE N/A
- PDYN N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- PDYN Wholesale Distributors
- Sector
- NGNE Health Care
- PDYN Industrials
- Exchange
- NGNE Nasdaq
- PDYN Nasdaq
- Market Cap
- NGNE 325.3M
- PDYN 271.4M
- IPO Year
- NGNE N/A
- PDYN N/A
- Fundamental
- Price
- NGNE $18.48
- PDYN $7.56
- Analyst Decision
- NGNE Strong Buy
- PDYN
- Analyst Count
- NGNE 7
- PDYN 0
- Target Price
- NGNE $41.86
- PDYN N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- PDYN 1.8M
- Earning Date
- NGNE 08-11-2025
- PDYN 08-06-2025
- Dividend Yield
- NGNE N/A
- PDYN N/A
- EPS Growth
- NGNE N/A
- PDYN N/A
- EPS
- NGNE N/A
- PDYN N/A
- Revenue
- NGNE N/A
- PDYN $4,357,000.00
- Revenue This Year
- NGNE N/A
- PDYN N/A
- Revenue Next Year
- NGNE N/A
- PDYN $97.52
- P/E Ratio
- NGNE N/A
- PDYN N/A
- Revenue Growth
- NGNE N/A
- PDYN N/A
- 52 Week Low
- NGNE $6.88
- PDYN $1.38
- 52 Week High
- NGNE $74.49
- PDYN $14.95
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- PDYN 44.00
- Support Level
- NGNE $19.59
- PDYN $6.85
- Resistance Level
- NGNE $20.46
- PDYN $8.12
- Average True Range (ATR)
- NGNE 1.23
- PDYN 0.40
- MACD
- NGNE -0.20
- PDYN 0.06
- Stochastic Oscillator
- NGNE 13.37
- PDYN 55.91
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About PDYN Palladyne AI Corp.
Palladyne AI Corp is a software company focused on autonomy for robotic systems and solutions. Its artificial intelligence and machine learning software seeks to revolutionize the capabilities of robots, enabling them to observe, learn, reason, and act in structured and unstructured environments. AI and ML software platform of the company empowers robots to perceive variations or changes in the real-world environment, enabling them to autonomously maneuver and manipulate objects accurately in response. Palladyne AI software has wide application, including in industries such as automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics and warehousing.